Moleculin Biotech: Preclinical Data Suggest Annamycin’s Pancreatic Activity Involves CD8+ T Cells

Moleculin Biotech announced preclinical data showing Annamycin’s antitumor activity in pancreatic cancer is partially mediated by CD8+ T cells.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Sep. 25, 2026This is an AI-powered summary. It may contain inaccuracies. Consid…